TEZEPELUMAB REDUCED OCS USE IN OCS-DEPENDENT PATIENTS WITH SEVERE ASTHMA: PHASE 3B WAYFINDER STUDY INTERIM RESULTS

被引：2

作者：

Jackson, D. J. ^{[1
,2
]}

Lugogo, N. ^{[3
]}

Gurnell, M. ^{[4
,5
]}

Heaney, L. G. ^{[6
]}

Korn, S. ^{[7
,8
]}

Brusselle, G. ^{[9
]}

Chanez, P. ^{[10
]}

Llanos, J-P ^{[11
]}

Martin, N. ^{[12
,13
]}

Keeling, N. ^{[14
]}

Salapa, K. ^{[15
]}

Cook, B. ^{[16
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Guys Severe Asthma Ctr, London, England

[2] Kings Coll London, Sch Immunol & Microbial Sci, London, England

[3] Univ Michigan, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI USA

[4] Univ Cambridge, Wellcome MRC Inst Metab Sci, Metab Res Labs, Cambridge, England

[5] Addenbrookes Hosp, Natl Inst Hlth Res, Cambridge Biomed Res Ctr, Cambridge, England

[6] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Sch Med Dent & Biomed Sci, Belfast, North Ireland

[7] IKF Pneumol Mainz, Mainz, Germany

[8] Thoraxklin Heidelberg, Heidelberg, Germany

[9] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium

[10] Aix Marseille Univ, Dept Resp Dis, Marseille, France

[11] Amgen Inc, Global Med Affairs, Thousand Oaks, CA USA

[12] AstraZeneca, Resp & Immunol, BioPharmaceut Med, Cambridge, England

[13] Univ Leicester, Leicester, England

[14] AstraZeneca, Global Med Affairs, Resp & Immunol, BioPharmaceut R&D, Gothenburg, Sweden

[15] AstraZeneca, Biometr Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Warsaw, Poland

[16] AstraZeneca, Resp & Immunol, BioPharmaceut Med, Gaithersburg, MD USA

来源：

关键词：

D O I：

10.1136/thorax-2023-BTSabstracts.71

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

S65

引用

页码：A49 / A49

页数：1